NEWAMSTERDAM PHARMA CO NV (NAMS) Stock News
NASDAQ:NAMS - Nasdaq - NL00150012L7 - Common Stock
NAMS Latest News and Analysis
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a...
Menarini Group gibt positive Topline-Daten aus den klinischen Phase-3-Studien BROADWAY und TANDEM zur Bewertung von Obicetrapib und der Fixkombination Obicetrapib mit Ezetimib 10 mg bekannt
- Beide entscheidenden Studien erreichten die primären Endpunkte der mittleren Senkung des LDL-Cholesterins zusätzlich zu maximal verträglichen lipidsenkenden...
Menarini Group annonce des données de base positives issues des essais cliniques pivots de phase 3 BROADWAY et TANDEM qui évaluent l'Obicetrapib et l'association à dose fixe d'Obicetrapib et d'Ézétimibe 10 mg
– Les deux études pivot s ont atteint les critères d'évaluation primaires de réduction moyenne par les moindres carrés (LS) du LDL-C en plus des thérapies de...
Menarini Group anuncia datos positivos de los ensayos clínicos fundamentales de fase 3 BROADWAY y TANDEM
– Menarini Group anuncia datos positivos de los ensayos clínicos fundamentales de fase 3 BROADWAY y TANDEM que evalúan obicetrapib y la combinación de dosis...
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical...
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
NAARDEN, The Netherlands and MIAMI, Dec. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a...
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
NAARDEN, the Netherlands and MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a...
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
NAARDEN, The Netherlands and MIAMI, Dec. 10, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a...
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?
On Tuesday, NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) revealed topline data from its Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. ASCVD is a chronic disease that occurs when plaque builds up in the walls of arteries, narrowing them and reducing blood flo
NewAmsterdam Pharma Soars 41% On An Surprise Benefit From Cholesterol Drug
The results bode well for an ongoing Phase 3 study examining cardiovascular outcomes.
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
-- Achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically...
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Dec. 06, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...
NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study
The company's combination treatment lowered LDL cholesterol by about 50% over 84 days.
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 – – Lp(a) mean reduction versus placebo of 45.9%...
Bullish Two Hundred Day Moving Average Cross - NAMS
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
– Topline data from pivotal Phase 3 TANDEM trial now expected in 4Q 2024 due to faster than expected enrollment – – On-track to report topline data from...
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Nov. 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...